The objective of the proposed study is to determine how the N-acetyltransferase (NAT) polymorphism, a genetic metabolic trait involved in the metabolism of arylamines, influences individual susceptibility to arylamine-induced DNA damage and carcinogenesis. The finding that there are two polymorphic NATs in humans, each with multiple alleles, adds a new dimension to the investigation of the role of acetylator status in human sensitivity to exogenous chemicals.In this proposal, molecular biological and cell culture techniques will be used to transfect specific alleles of human NATs into mammalian cells (COS cells) and then to determine the susceptibility of the resulting genotype to arylamine-induced DNA damage. Current studies using acetylator congenic and acetylator, Ah-responder double congenic mouse lines will be extended to additional carcinogens and tissues. Further studies will focus on the interaction of the NAT polymorphism with two alternative oxidation pathways for arylamine carcinogens: cytochrome P450 1A subfamily monooxygenases and prostaglandin synthase (PHS) co-oxidation. Inbred and congenic mouse lines that are being developing in this laboratory will be used to model the interaction of NAT with cytochrome P450 1A and NAT with PHS as determinants of human susceptibility to colon and other extra-hepatic cancers. The technique of 32P-postlabeling (and the HPLC method previously developed in this laboratory) will be used to determine genotype-specific and tissue-specific patterns of DNA damage resulting from carbocyclic aromatic amines (e.g. 2-aminofluorene) and heterocyclic aromatic amines (e.g. IQ) produced in cooked foods. An inbred mouse model will also be constructed to determine the contribution of PHS and combinations of PHS and NAT to extra-hepatic DNA damage induced by these aryl- and heterocyclic amines. This model will also be used as a tool to study pharmacological interventions in PHS activity and their effects on prevention or reduction of DNA damage and carcinogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA039018-12
Application #
2458036
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1985-01-01
Project End
1999-07-31
Budget Start
1997-08-01
Budget End
1998-07-31
Support Year
12
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
de Leon, J H; Vatsis, K P; Weber, W W (2000) Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol 58:288-99
Dhaini, H R; Levy, G N (2000) Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population. Pharmacogenetics 10:79-83
Estrada, L; Kanelakis, K C; Levy, G N et al. (2000) Tissue- and gender-specific expression of N-acetyltransferase 2 (Nat2*) during development of the outbred mouse strain CD-1. Drug Metab Dispos 28:139-46
Weber, W W (1999) Populations and genetic polymorphisms. Mol Diagn 4:299-307
Liu, Y; Levy, G N (1998) Activation of heterocyclic amines by combinations of prostaglandin H synthase-1 and -2 with N-acetyltransferase 1 and 2. Cancer Lett 133:115-23
Estrada-Rodgers, L; Levy, G N; Weber, W W (1998) Characterization of a hormone response element in the mouse N-acetyltransferase 2 (Nat2*) promoter. Gene Expr 7:13-24
Estrada-Rodgers, L; Levy, G N; Weber, W W (1998) Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells. Drug Metab Dispos 26:502-5
Liu, Y; Levy, G N; Weber, W W (1997) Induction of human prostaglandin endoperoxide H synthase-2 (PHS-2) mRNA by TCDD. Prostaglandins 53:1-10
Levy, G N (1997) Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 11:234-47
Levy, G N; Rodgers, L; Weber, W W (1996) Effects of heredity on response to drugs and environmental chemicals: construction of rodent models. Chem Res Toxicol 9:1215-24

Showing the most recent 10 out of 27 publications